A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment  

作　　者：Valentina Marotti Yining Xu Cécilia Bohns Michalowski Wunan Zhang Inês Domingues Hafsa Ameraoui Tom G.Moreels Pieter Baatsen Matthias Van Hul Giulio G.Muccioli Patrice D.Cani Mireille Alhouayek Alessio Malfanti Ana Beloqui 

机构地区：[1]UCLouvain,Universit´e catholique de Louvain,Louvain Drug Research Institute,Advanced Drug Delivery and Biomaterials,1200 Brussels,Belgium [2]UCLouvain,Universit´e catholique de Louvain,Louvain Drug Research Institute,Bioanalysis and Pharmacology of Bioactive Lipids,1200 Brussels,Belgium [3]UCLouvain,Universit´e catholique de Louvain,Institute of Experimental and Clinical Research,Laboratory of Hepato-Gastroenterology,1200 Brussels,Belgium [4]Cliniques universitaires Saint-Luc,Department of Hepato-Gastroenterology,Brussels,Belgium [5]EM-platform,VIB Bio Imaging Core,KU Leuven,Campus Gasthuisberg,Herestraat 49,3000 Leuven,Belgium [6]UCLouvain,Universit´e catholique de Louvain,Louvain Drug Research Institute,Metabolism and Nutrition Group,1200 Brussels,Belgium [7]UCLouvain,Institute of Experimental and Clinical Research,1200 Brussels,Belgium [8]WEL Research Institute,Avenue Pasteur,6,1300 Wavre,Belgium

出　　处：《Bioactive Materials》2024年第2期206-221,共16页生物活性材料（英文）

基　　金：Belgian F.R.S.-FNRS(Fonds de la recherche scientifique)under grants WELBIO-CR-2022A-02;The Excellence Of Science(EOS:program no.EOS 30770923 and 40007505);supported by the Marie Skłodowska-Curie Actions for an Individual European Fellowship under the European Union’s Horizon 2020 research and innovation program(grant agreement no.887609);by a FRS-FNRS fellowship(grant agreement no.40000747)(Belgium);partially supported by the FRS-FNRS(convention T.0013.19);FRFS-WELBIO,with the support of the Wallon region(under grant agreement WELBIO-CR-2022 S-01);has received funding from the European Research Council(ERC)under the European Union’s Horizon 2020 research and innovation program(grant agreement No.850997-NanoGut).

摘　　要：Current treatments for inflammatory bowel disease(IBD)treatment consist of anti-inflammatory products.In this study,we sought to induce the physiological secretion of glucagon-like peptide 2,a peptide with intestinal growth-promoting activity,via nanoparticles while simultaneously providing with immunomodulation by tailoring the nanoparticle surface.To this end,we developed hybrid lipid hyaluronate-KPV conjugated nanoparticles loaded with teduglutide for combination therapy in IBD.The nanocarriers induced(or did not induce)immunosuppression depending on the presence(or absence)of a hyaluronan-KPV functionalization.This strategy holds promise as a nanoparticle platform for combined mucosal healing and immunomodulation in IBD treatment.

关 键 词：NANOCARRIER GLP-2 Teduglutide KPV Inflammatory bowel disease 

分 类 号：R574[医药卫生—消化系统] R318[医药卫生—内科学]